View in EDS PDF Full Text

Novartis: The Challenge of Success (A)

Saved in:
Bibliographic Details
Title: Novartis: The Challenge of Success (A)
Description: Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the unexpected data processed by Alex Matter, head of oncology research at Novartis, AG. CML was a rare form of cancer that affected a very small number of individuals in the world. The development of STI571 was a pioneering concept in genetically targeted drug development. This case enables students to decide whether and how they would advance the development, production, and distribution of the drug given these extraordinarily successful Phase 1 results. Provides details on factors that complicate this decision, including production complexity, precedents from other high-profile drug treatments, and market pressures.
Authors: Sandra J. Sucher, Stacy McManus
Resource Type: eBook.
Categories: BUSINESS & ECONOMICS / General
Database: eBook Collection (EBSCOhost)
FullText Links:
  – Type: ebook-pdf
Text:
  Availability: 0
Header DbId: nlebk
DbLabel: eBook Collection (EBSCOhost)
An: 2303059
RelevancyScore: 985
AccessLevel: 6
PubType: eBook
PubTypeId: ebook
PreciseRelevancyScore: 985.343994140625
IllustrationInfo
ImageInfo – Size: thumb
  Target: https://rps2images.ebscohost.com/rpsweb/othumb?id=NL$2303059$PDF&s=r
– Size: medium
  Target: https://rps2images.ebscohost.com/rpsweb/othumb?id=NL$2303059$PDF&s=d
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Novartis: The Challenge of Success (A)
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the unexpected data processed by Alex Matter, head of oncology research at Novartis, AG. CML was a rare form of cancer that affected a very small number of individuals in the world. The development of STI571 was a pioneering concept in genetically targeted drug development. This case enables students to decide whether and how they would advance the development, production, and distribution of the drug given these extraordinarily successful Phase 1 results. Provides details on factors that complicate this decision, including production complexity, precedents from other high-profile drug treatments, and market pressures.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Sandra+J%2E+Sucher%22">Sandra J. Sucher</searchLink><br /><searchLink fieldCode="AR" term="%22Stacy+McManus%22">Stacy McManus</searchLink>
– Name: TypePub
  Label: Resource Type
  Group: TypPub
  Data: eBook.
– Name: SubjectBISAC
  Label: Categories
  Group: Su
  Data: <searchLink fieldCode="ZK" term="%22BUSINESS+%26+ECONOMICS+%2F+General%22">BUSINESS & ECONOMICS / General</searchLink>
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=nlebk&AN=2303059
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Novartis: The Challenge of Success (A)
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sandra J. Sucher
      – PersonEntity:
          Name:
            NameFull: Stacy McManus
      – PersonEntity:
          Name:
            NameFull: Sandra J. Sucher
      – PersonEntity:
          Name:
            NameFull: Stacy McManus
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Type: published
              Y: 2003
          Titles:
            – TitleFull: Novartis: The Challenge of Success (A)
              Type: main
ResultId 1